The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 22, 2016

Filed:

Jul. 21, 2012
Applicants:

Shulong Wang, Hangzhou, CN;

Jian Cai, Hangzhou, CN;

Qiufu GE, Hangzhou, CN;

Dianwu Guo, Hangzhou, CN;

Lan Yang, Hangzhou, CN;

Binnan Huang, Hangzhou, CN;

Zhenhua Liu, Hangzhou, CN;

Zhonghua Peng, Hangzhou, CN;

Ximing Shen, Hangzhou, CN;

Feiyu Feng, Hangzhou, CN;

Inventors:

Shulong Wang, Hangzhou, CN;

Jian Cai, Hangzhou, CN;

Qiufu Ge, Hangzhou, CN;

Dianwu Guo, Hangzhou, CN;

Lan Yang, Hangzhou, CN;

Binnan Huang, Hangzhou, CN;

Zhenhua Liu, Hangzhou, CN;

Zhonghua Peng, Hangzhou, CN;

Ximing Shen, Hangzhou, CN;

Feiyu Feng, Hangzhou, CN;

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 417/04 (2006.01); C07D 405/14 (2006.01); C07D 405/04 (2006.01); C07D 403/14 (2006.01);
U.S. Cl.
CPC ...
C07D 417/04 (2013.01); C07D 403/14 (2013.01); C07D 405/04 (2013.01); C07D 405/14 (2013.01);
Abstract

A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.


Find Patent Forward Citations

Loading…